Preclinical models suggest BPC-157 repairs esophageal tissue faster than omeprazole at 14 days, but PPIs have decades of human safety data and FDA approval BPC-157 has neither
3.6 Cognitive disorders Most patients seem to return to normal life after infection with C-19, but many remain with mild symptoms that are often attributed to other daily factors such as fatigue, memory problems, and loss of attention, without realizing that these symptoms may be long-term symptoms caused by C-19 infection (68)
Mechanism of action, what it does at the cellular level Here is the key difference from most drugs: BPC-157 does not function like a classical drug
Function: Helps blend active ingredients into a smooth smoothie consistency and adds a fuller taste to the formula without the need for sugar or sweeteners
Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC) JCO